Technical Analysis for ADVM - Adverum Biotechnologies, Inc.
|Grade||Last Price||% Change||Price Change|
ADVM closed down 1.25 percent on Thursday, January 17, 2019, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Down||Down|
|See historical ADVM trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||MACD Bearish Signal Line Cross||Bearish||0.00%|
|Jan 17||Narrow Range Bar||Range Contraction||0.00%|
|Jan 17||NR7||Range Contraction||0.00%|
|Jan 16||Fell Below 20 DMA||Bearish||-1.25%|
|Jan 16||180 Bearish Setup||Bearish Swing Setup||-1.25%|
|Jan 16||Outside Day||Range Expansion||-1.25%|
|Jan 15||Crossed Above 20 DMA||Bullish||-5.69%|
|Jan 15||Inside Day||Range Contraction||-5.69%|
|Jan 14||Fell Below 20 DMA||Bearish||-1.56%|
|Jan 14||Fell Below 50 DMA||Bearish||-1.56%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ADVM news...
|52 Week High||8.59|
|52 Week Low||2.62|
|200-Day Moving Average||5.1228|
|50-Day Moving Average||3.5136|
|20-Day Moving Average||3.308|
|10-Day Moving Average||3.411|
|Average True Range||0.2245|
|Chandelier Exit (Long, 3 ATRs )||3.0265|
|Chandelier Exit (Short, 3 ATRs )||3.4835|
|Upper Bollinger Band||3.6927|
|Lower Bollinger Band||2.9233|
|Percent B (%b)||0.29|
|MACD Signal Line||-0.0792|
|Market Cap||136.36 Million|
|Num Shares||43.3 Million|
|Price-to-Earnings (P/E) Ratio||-2.07|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.31|
|Resistance 3 (R3)||3.31||3.26||3.28|
|Resistance 2 (R2)||3.26||3.22||3.26||3.27|
|Resistance 1 (R1)||3.21||3.20||3.18||3.20||3.26|
|Support 1 (S1)||3.10||3.12||3.08||3.10||3.04|
|Support 2 (S2)||3.05||3.09||3.05||3.03|
|Support 3 (S3)||3.00||3.05||3.02|
|Support 4 (S4)||2.99|